The book covers the latest scientific advances in biomarker identification, sensor design, and point-of-care diagnostic systems tailored for early-stage prostate cancer. It explains how biosensors function, their role in overcoming limitations of traditional diagnostic tools, and their impact on personalized medicine.
The book focuses on integrating interdisciplinary knowledge, combining insights from biotechnology, nanotechnology, and clinical oncology. It includes chapters that explain different types of biosensors, electrochemical, optical, and nanomaterial-based, while discussing their real-world applications and clinical relevance.
A special chapter is dedicated to prostate cancer-specific biomarkers and sensor platforms, providing readers with a focused understanding of disease-targeted diagnostics.
This book benefits researchers, clinicians, biomedical engineers, and graduate students by offering practical insights and future directions in diagnostic innovation. It serves as a valuable resource for anyone aiming to improve early detection and management of prostate cancer, making it essential for academic, research, and clinical settings.
Chapter 1: Introduction to Prostate Cancer.
Chapter 2: The Role of
Biomarkers in Prostate Cancer Diagnosis.
Chapter 3: Fundamentals of
Biosensors.
Chapter 4: Electrochemical Biosensors for Prostate Cancer.-
Chapter 5: Optical Biosensors: Techniques and Applications against prostate
cancer.
Chapter 6: Magnetic Biosensors: Innovations in Detection of Prostate
Cancer.
Chapter 7: Nanotechnology-based Biosensor Development for prostate
cancer detection.
Chapter 8: Point-of-Care Testing for Prostate Cancer.-
Chapter 9: Multiplex Biosensing Platforms for prostate cancer.
Chapter 10:
Data analysis from Biosensors by ML and AI in the detection of prostate
cancer.
Chapter 11: Current Challenges in Prostate Cancer Biosensing.-
Chapter 12: Regulatory Considerations for Biosensor Development for prostate
cancer.
Shriyansh Srivastava holds a B. Pharmacy degree from Dr. A.P.J. Abdul Kalam Technical University, Lucknow, Uttar Pradesh, India, and an M. Pharmacy (Pharmacology) degree from ISF College of Pharmacy, Moga, Punjab, India. PhD in Pharmacology & Clinical Research at Delhi Pharmaceutical Sciences and Research University, New Delhi, India. He is currently serving as a guest editor for BMC Microbiology, a Springer Nature (Q1) Journal, with an IF of 4.2. He actively engages in cutting-edge research and has published over 75+ research and review articles in prestigious international journals. His work in the Lancet series, including Lancet Microbe, with an impact factor of 38.2, highlights his scholarly excellence and contributes to a cumulative impact factor of over 250+. Shriyansh has secured three patents and authored 15 book chapters in his field. Currently, he is editing 11 academic books with major publishers, including Elsevier, Wiley, Springer, and Taylor & Francis. He is a potential reviewer in Elsevier, Springer, Taylor & Francis, and Wiley Journals. His strong educational and research background make him a leading voice in pharmacology and virology.
Dr. Molakpogu Ravindra Babu is currently serving as a Professor and Program Chair in Department of Pharmacy, School of Medical & Allied Sciences, Galgotias University. Previously he served as a professor in Lovely Professional University, Punjab, India. Dr. Babu has a vast experience of more than 15 years in teaching and research. His key research area includes development of minimal invasive drug delivery systems and nano delivery systems. He has guided 12 M. Pharm projects and 35 B. Pharm Projects. He is currently working on microneedle technology and various lipid based nanoparticulate delivery systems. He published 2 books in Springer Nature and 15 book chapters in various publishers including Elsevier, Springer, Taylor, and Francis. Currently, he is editing two books with Springer Nature and 3 books with Wiley publishers. Dr. Babu is serving as a reviewer for number of reputed journals of Springer Nature, Elsevier, and Bentham Publishers. He is having a cumulative impact factor of more than 300 and H-index of 12.
Dr. Shashank Shekhar is an Associate Professor in the Department of Radiotherapy at AIIMS Gorakhpur. He holds an MD in Radiotherapy from Maulana Azad Medical College, Delhi University. With a strong background in clinical oncology and pharmacovigilance, Dr. Shekhar has contributed to multiple peer-reviewed publications and participates actively in ethical oversight as a member of the Institutional Human Ethics Committee. His academic and clinical interests focus on advancing patient safety and cancer treatment practices in India.
